Mitochondrion‐Targeted Type I Photodynamic Therapy for Agonist Independent cGAS‐STING Activation
Advanced Materials · 2025-04 · 37 (14)
DOI: 10.1002/adma.202418894 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 23.02.2025. Verfasst von Yin Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry & Materials Science, Jiangsu Normal University, 101 Shanghai Road, Xuzhou, 221116, China. Hauptthemen laut MEDLINE: Photochemotherapy, Mitochondria, Photosensitizing Agents, Membrane Proteins. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Research of Jiangsu Higher Education Institutions of China, Xuzhou Municipal Science and Technology Bureau.
Abstract (Originalsprache)
CGAS‐STING agonists generally lead to hyperimmunity and systemic toxicity, hindering their immunotherapeutic outcomes. Herein, a mitochondrion‐targeted nanoagonist (termed HABH) containing boron dipyrromethene (BODIPY)‐derived type I photosensitizer (BDP) and Au nanoparticle‐engineered hollow mesoporous silica (HMSN/AuNPs) has been fabricated for light‐controlled mitochondrial stress‐inducing and agonist‐independent cGAS‐STING pathway activation. The HABH nanoagonist can actively target tumor tissues and release the mitochondrion‐targeted BDP. Under light illumination, BDP achieves type I photodynamic therapy (PDT) in mitochondria, generating massive hydroxyl radicals (•OH) and inducing mitochondrial stress in an oxygen‐independent manner, promoting the release of mitochondrial DNA (mtDNA). Simultaneously, the HMSN/AuNPs act as dual nanozymes to derive cascade reactions for •OH production, elevating the intracellular oxidative state, and together with the BDP‐induced mitochondrial stress, finally evoking the cGAS‐STING pathway and facilitating the release of type I interferon. In the orthotopic breast tumor models, the HABH nanoagonist achieved intratumoral and systemic immunoactivation for eradicating primary tumors and preventing metastasis tumors. Therefore, the constructed mitochondrion‐targeted nanoagonist enabled light‐controlled and agonist‐independent cGAS‐STING activation, providing a paradigm for photoimmunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry & Materials Science, Jiangsu Normal University, 101 Shanghai Road, Xuzhou, 221116, China.
- State Key Laboratory of Flexible Electronics (LoFE) & Institute of Advanced Materials (IAM), School of Flexible Electronics (Future Technologies), Nanjing Tech University (NanjingTech), Nanjing, 211816, China.
ORCID-Profile: Xiaochen Dong
Förderung
- National Natural Science Foundation of China
- Natural Science Research of Jiangsu Higher Education Institutions of China
- Xuzhou Municipal Science and Technology Bureau
Zitieren
APA
Xu, Y., An, D., Zhang, T., Wu, X., Wang, S., Shao, J., Qu, L. L., Guo, Y., & Dong, X. (2025). Mitochondrion‐Targeted Type I Photodynamic Therapy for Agonist Independent cGAS‐STING Activation. Advanced Materials, 37(14). https://doi.org/10.1002/adma.202418894
Vancouver
Xu Y, An D, Zhang T, Wu X, Wang S, Shao J, et al. Mitochondrion‐Targeted Type I Photodynamic Therapy for Agonist Independent cGAS‐STING Activation. Advanced Materials. 2025;37(14). doi:10.1002/adma.202418894
BibTeX
@article{Xu2025,
author = {Xu, Yin and An, Daokuan and Zhang, Tian and Wu, Xiaochen and Wang, Shuang and Shao, Jinjun and Qu, Lu-Lu and Guo, Yuxin and Dong, Xiaochen},
title = {Mitochondrion‐Targeted Type I Photodynamic Therapy for Agonist Independent cGAS‐STING Activation},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {14},
doi = {10.1002/adma.202418894}
}
EUVIMED